This is a routine executive hire with no immediate trading catalyst. Monitor for future pipeline updates on KIO-301 and KIO-104, which Lane will oversee. No position adjustment warranted based on this filing alone.
Price Chart
Executive Summary
Kiora Pharmaceuticals appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, effective September 8, 2026. Lane brings over 20 years of ophthalmology experience from Ora, Inc., including oversight of 12 global Phase 3 pivotal studies. This is a routine executive hire with no financial data or guidance provided, making it a neutral event for the stock.
Key Facts
- Keith Lane appointed EVP, Head of Clinical Development and Regulatory Affairs effective September 8, 2026.
- Lane previously served as Chief Scientific Officer at Ora, Inc., overseeing 60+ ophthalmic trials including 12 global Phase 3 pivotal studies.
- Compensation includes $350,000 annual base salary, $75,000 sign-on bonus, and 55,000 stock options vesting over 3 years.
- No financial results, guidance, or material business developments were disclosed in the filing.
Financial Impact
No financial impact disclosed; executive compensation is routine and immaterial relative to market cap.
Risk Factors
- No financial data or guidance provided; the filing lacks material business updates.
- Clinical-stage biotech with $11M market cap; pipeline execution risk remains high.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001372514-26-000079 |
| Exhibit: exhibit-101xkeithlane.htm | 0001372514-26-000079 |
| Exhibit: ex991-pressreleasekeithlan.htm | 0001372514-26-000079 |
| Document: 0001372514-26-000079-index-headers.html | 0001372514-26-000079 |
| Document: 0001372514-26-000079-index.html | 0001372514-26-000079 |
| Document: 0001372514-26-000079.txt | 0001372514-26-000079 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 7w ago | 8-K | $2.51 $2.50 | ▼ −0.40% | ▼ −2.37% | $2.27 (−9.56%) |
Aug 19, 2026 9w ago | 8-K | $2.60 $2.67 | ▲ +2.69% | ▲ +4.64% | $2.27 (−12.69%) |
Aug 7, 2026 11w ago | 8-K | $2.64 $2.55 | ▼ −3.41% | ▼ −3.01% | $2.27 (−14.02%) |
Jun 18, 2026 18w ago | 8-K | $2.53 $2.55 | ▲ +0.79% | ▲ +0.26% | $2.27 (−10.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers